- Report
- February 2024
- 168 Pages
Global
From €5660EUR$6,360USD£4,982GBP
€7074EUR$7,950USD£6,227GBP
- Report
- July 2023
- 67 Pages
Global
From €2812EUR$3,160USD£2,475GBP
€3515EUR$3,950USD£3,094GBP
- Report
- February 2024
- 112 Pages
Global
From €4227EUR$4,750USD£3,721GBP
- Report
- May 2024
- 139 Pages
Global
From €4916EUR$5,524USD£4,327GBP
€5783EUR$6,499USD£5,091GBP
- Report
- November 2023
- 189 Pages
Global
From €4004EUR$4,500USD£3,525GBP
- Report
- June 2023
- 204 Pages
Global
From €3204EUR$3,600USD£2,820GBP
- Report
- June 2023
- 84 Pages
North America
From €1335EUR$1,500USD£1,175GBP
- Report
- June 2023
- 94 Pages
Africa, Middle East
From €1335EUR$1,500USD£1,175GBP
- Report
- June 2023
- 92 Pages
Asia Pacific
From €1335EUR$1,500USD£1,175GBP
- Report
- June 2023
- 92 Pages
Europe
From €1335EUR$1,500USD£1,175GBP
- Report
- November 2023
- 140 Pages
Global
From €3960EUR$4,450USD£3,486GBP
- Report
- December 2023
- 168 Pages
Global
From €4404EUR$4,949USD£3,877GBP
- Report
- February 2023
- 70 Pages
Global
From €3110EUR$3,495USD£2,738GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more